Preview

Медицинский Совет

Расширенный поиск

Роль мелатонина в терапии хронической головной боли

https://doi.org/10.21518/2079-701X-2018-1-33-37

Полный текст:

Аннотация

Мелатонин – эндогенный хронобиотик, продемонстрировавший в ряде экспериментальных и клинических работ свои анальгетические возможности. Он оказался эффективен при фибромиалгии, синдроме раздраженного кишечника, боли в спине и различных типах головной боли. Наиболее высокий уровень доказательности анальгетических свойств мелатонина при мигрени и кластерной головной боли. В данном обзоре рассмотрены основные работы, имеющиеся на данный момент, где мелатонин используется при первичных головных болях различного типа. Обсуждаются возможные механизмы реализации мелатонином анальгетического действия и перспективы его использования в комплексной терапии головной боли.

 

Об авторах

Ю. М. Курганова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


А. Б. Данилов
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
д.м.н., профессор


Список литературы

1. Brzezinski A. Melatonin in humans. The New England journal of medicine, 1997, 336: 186–195.

2. Ferrari E, Nappi G, Vailati A, Martignoni E, Bossolo PA, Polleri A. Circadian periodicity of plasma prolactin in some neurological diseases. International journal of chronobiology, 1979, 6: 231–242.

3. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain, 2014, 137: 232–241.

4. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet, 1998, 352: 275–278.

5. Weaver DR, Stehle JH, Stopa EG, Reppert SM. Melatonin receptors in human hypothalamus and pituitary: implications for circadian and reproductive responses to melatonin. The Journal of clinical endocrinology and metabolism, 1993, 76: 295–301.

6. Wu YH, Ursinus J, Zhou JN, et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. Journal of affective disorders, 2013, 148: 357–367.

7. Nagtegaal JE, Smits MG, Swart AC, Kerkhof GA, van der Meer YG. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. Headache, 1998, 38: 303–307.

8. Leone M, Frediani F, D’Amico D, et al. Dexamethasone suppression test, melatonin and TRH-test in cluster headache. Italian journal of neurological sciences, 1992, 13: 227–232.

9. Leone M, Lucini V, D’Amico D, et al. Twenty-four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia: an international journal of headache, 1995, 15: 224–229.

10. Chazot G, Claustrat B, Brun J, Jordan D, Sassolas G, Schott B. A chronobiological study of melatonin, cortisol growth hormone and prolactin secretion in cluster headache. Cephalalgia: an international journal of headache, 1984, 4: 213–220.

11. Waldenlind E, Gustafsson SA, Ekbom K, Wetterberg L. Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission. Journal of neurology, neurosurgery, and psychiatry, 1987, 50: 207–213.

12. Woldeamanuel YW, Cowan RP. The impact of regular lifestyle behavior in migraine: a prevalence case-referent study. Journal of neurology, 2016, 263 (4): 669–676.

13. Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache, 2005, 45: 904–910.

14. Ahn AH, Brennan KC. Unanswered questions in headache: how does a migraine attack stop? Headache, 2012, 52: 186–187.

15. El-Shenawy SM, Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS. Studies on the anti- inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacological research, 2002, 46: 235–243.

16. Gitto E, Aversa S, Salpietro CD, et al. Pain in neonatal intensive care: role of melatonin as an analgesic antioxidant. Journal of pineal research, 2012, 52: 291–295.

17. Marseglia L, Manti S, D’Angelo G, et al. Potential Use of Melatonin in Procedural Anxiety and Pain in Children Undergoing Blood Withdrawal. Journal of biological regulators and homeostatic agents, 2015, 29: 509–514.

18. Galley HF, Lowes DA, Allen L, Cameron G, Aucott LS, Webster NR. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. Journal of pineal research, 2014, 56: 427–438.

19. Gonzalez R, Sanchez A, Ferguson JA, et al. Melatonin therapy of advanced human malignant melanoma. Melanoma research, 1991, 1: 237–243.

20. Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology, 2010, 75: 1527–1532.

21. Leone M, D’Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia: an international journal of headache, 1996, 16: 494–496.

22. Peres M, Goncalves A. Double-Blind, Placebo Controlled, Randomized Clinical Trial Comparing Melatonin 3 mg, Amitriptyline 25 mg and Placebo for Migraine Prevention. Neurology. 2013, 80: S40.005.

23. Masruha MR, de Souza Vieira DS, Minett TS, et al. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. The journal of headache and pain, 2008, 9: 221–224.

24. Masruha MR, Lin J, de Souza Vieira DS, et al. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache, 2010, 50: 413–419.

25. Bougea A, Spantideas N, Lyras V, Avramidis T, Thomaidis T. Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. Functional neurology, 2016: 1–5.

26. Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Current drug safety, 2015, 10: 132–135.

27. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, 29: 285–287.

28. Bruera O, Sances G, Leston J, et al. Plasma melatonin pattern in chronic and episodic headaches: evaluation during sleep and waking. Functional neurology, 2008, 23: 77–81.

29. Leone M, Lucini V, D’Amico D, et al. Abnormal 24-hour urinary excretory pattern of 6- sulphatoxymelatonin in both phases of cluster headache. Cephalalgia: an international journal of headache, 1998, 18: 664–667.

30. Waldenlind E, Ekbom K, Wetterberg L, et al. Lowered circannual urinary melatonin concentrations in episodic cluster headache. Cephalalgia: an international journal of headache, 1994, 14: 199– 204.

31. Leone M, Bussone G. A review of hormonal findings in cluster headache. Evidence for hypothalamic involvement. Cephalalgia: an international journal of headache, 1993, 13: 309–317.

32. Peres MF, Stiles MA, Oshinsky M, Rozen TD. Remitting form of hemicrania continua with seasonal pattern. Headache, 2001, 41: 592–594.

33. Rozen TD. How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study. Headache, 2015, 55: 430–436.

34. Hollingworth M, Young TM. Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache. Headache, 2014, 54: 916–919.

35. Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache, 2006, 46: 524–527.

36. De Simone R, Marano E, Ranieri A, Bonavita V. Hypnic headache: an update. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2006, 27(Suppl 2): S144–S148.

37. Iguichi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. The Journal of clinical endocrinology and metabolism, 1982, 55: 27–29.

38. Dodick DW. Polysomnography in hypnic headache syndrome. Headache, 2000, 40: 748–752.

39. Domitrz I. Hypnic headache as a primary short-lasting night headache: a report of two cases. Neurologia i neurochirurgia polska, 2005, 39: 77–79.

40. Holle D, Naegel S, Krebs S, et al. Clinical characteristics and therapeutic options in hypnic headache. Cephalalgia: an international journal of headache, 2010, 30: 1435–1442.

41. Rozen TD. Melatonin as treatment for idiopathic stabbing headache. Neurology, 2003, 61: 865–866.

42. Rojas-Ramirez MV, Bertoli E, Smith JH. Short-Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing Secondary to Head and Neck Trauma: Literature Review and Case Report. Journal of oral & facial pain and headache, 2016, 30: 68–72.

43. Esposito E, Paterniti I, Mazzon E, Bramanti P, Cuzzocrea S. Melatonin reduces hyperalgesia associated with inflammation. Journal of pineal research, 2010, 49: 321–331.

44. Cardinali DP, Golombek DA. The rhythmic GABAergic system. Neurochemical research, 1998, 23: 607–614.

45. Shavali S, Ho B, Govitrapong P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain research bulletin, 2005, 64: 471–479.

46. Amir Aslani B, Ghobadi S. Studies on oxidants and antioxidants with a brief glance at their relevance to the immune system. Life sciences, 2016, 146: 163–173.

47. Yu C, Wu G, Xu S, Chen C. Effect of melatonin on release of endogenous opioid peptides in rat periaqueductal gray. Sheng Li Xue Bao, 2000, 52: 207- 210.

48. Hernández-Pacheco A, Araiza-Saldaña C, Granados-Soto V, Mixcoatl- Zecuatl T. Possible participation of the nitric oxide-cyclic GMP-protein kinase G-K+ channels pathway in the peripheral antinociception of melatonin. Europ J of Pharmacol, 2008, 596(1-3): 70-76.

49. Nelson C, Marino J, Allen C. Melatonin receptors activate heteromeric G- protein coupled Kir3 channels. Neuro Report, 1996, 7(2): 717-720.

50. Van Den Top M, Buijs R, Ruiijter J, Delagrande P, Spanswick D, Hermes L. Melatonin generates an outward potassium current in rat sup-raquias- matic nucleus neurons in vitro independent of their circadian rhythm. Neuroscience, 2001, 107(1): 99-108.

51. Ayar A, Duncan J, Ozcan M, Кelestimur H. Melatonin inhibits high voltage activated calcium currents in rat dorsal root ganglion neurons. Neuroscience Letters, 2001, 313(1-2): 73-77.

52. Coloma F, Niles L. Melatonin enhancement of [3H]-gamma-aminobutyric acid and [3H] mus-cimol binding in rat brain. Biochemical Pharmacology, 1988, 37(7): 1271-1274.

53. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC medicine, 2010, 8: 51.

54. Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. Journal of pineal research, 2009, 47: 1–7.

55. Andersen LP, Gogenur I, Rosenberg J, Reiter RJ. The Safety of Melatonin in Humans. Clinical drug investigation, 2016, 36: 169–175.

56. Курганова Ю.М., Данилов А.Б. Мелатонин при боли в спине и предикторы его эффективности. Журнал неврологии и психиатрии им. С.С. Корсакова, 2017, 111(10): 49-54.


Просмотров: 172


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)